• Fenipentol: From Choleresis to Translational Biology

  2026-08-12

  Fenipentol, also known as 1-Phenyl-1-pentanol, offers a distinctive bridge between historical secretion physiology, ESR1-linked molecular hypotheses, and modern translational study design. This thought-leadership article explains how to validate its biology without conflating it with the related but chemically distinct 1-Phenyl-2-Pentanol, identified in recent hepatic stellate cell research.

• PPT: An ERα Perturbation Framework for LUAD

  2026-08-11

  PPT (Propyl Pyrazole Triol) is more than a selective ERα agonist: it can serve as a causal perturbation tool for separating receptor biology from biomarker correlation. This guide connects PPT assay design with FOXM1–ERα findings in female lung adenocarcinoma while defining practical controls, limits, and translational opportunities.

• TBST for Cleaner Immunoassay Signal

  2026-08-11

  TBST combines isotonic buffering with mild non-ionic detergent action to reduce nonspecific binding in Western blotting, immunofluorescence, immunohistochemistry, and immunocytochemistry. Its greatest practical value is workflow consistency: one defined buffer can support blocking, antibody dilution, and post-incubation washing while preserving interpretable target-specific signal.

• Annexin V-FITC/PI Apoptosis Assay Kit Workflow

  2026-08-10

  Use Annexin V-FITC and PI staining to separate viable, early apoptotic, and membrane-compromised cells in a rapid, two-parameter workflow. This guide translates findings from a conjugated linoleic acid study into practical assay design, gating, optimization, and troubleshooting for intestinal epithelial injury models.

• CHIR 99021 Trihydrochloride for Organoid Assays

  2026-08-09

  CHIR 99021 trihydrochloride is a selective GSK-3 inhibitor for studying stem-cell state, intestinal organoid composition, insulin signaling, and glucose metabolism. This article presents an assay-design framework that separates pathway engagement from proliferation and differentiation outcomes.

• LY364947: TGF-β Type I Receptor Kinase Inhibitor

  2026-08-08

  LY364947 gives researchers a reversible way to interrogate TGF-β-driven Smad2 signaling, EMT, fibrosis, and retinal injury responses. This practical guide covers solvent handling, pathway-resolved assay design, combination studies inspired by pancreatic cancer research, and troubleshooting strategies.

• 2-Deoxy-D-glucose in Immunometabolism Assays

  2026-08-07

  Discover how 2-Deoxy-D-glucose can function as a calibrated metabolic perturbation in whole-blood immune assays, not merely as a glycolysis inhibitor. This guide connects assay design, cytokine interpretation, cancer metabolism, and viral research while distinguishing established evidence from practical recommendations.

• Targeted mRNA Delivery to Islet β Cells via Lipid Nanopartic

  2026-08-07

  A recent study demonstrates the use of conjugated lipid nanoparticles for efficient and selective mRNA delivery to pancreatic islet β cells in both mouse and human models. By enabling functional expression of PD-L1 mRNA, this platform delays autoimmune diabetes progression, highlighting a promising avenue for β cell-directed therapies and immune modulation.

• Stiripentol: LDH Inhibitor for Astrocyte-Neuron Lactate Modu

  2026-08-06

  Stiripentol is a noncompetitive LDH inhibitor that modulates lactate-to-pyruvate conversion, essential for astrocyte-neuron metabolic coupling and Dravet syndrome research. Its validated mechanism and robust solubility make it a key tool for epilepsy research and metabolic pathway dissection.

• ATG4B Nuclear Translocation Links Energy Deficiency to DNA R

  2026-08-06

  This study elucidates a novel mechanism by which cellular energy deficiency impairs DNA repair in acute myeloid leukemia (AML) via ATG4B nuclear translocation, which inhibits PRMT1-mediated methylation of MRE11. These findings highlight a key pathway connecting metabolic stress to genomic instability and offer new directions for targeted intervention in leukemia progression.

• Energy Deficiency, ATG4B, and DNA Repair in AML Progression

  2026-08-05

  This article reviews new evidence connecting cellular energy deficiency to impaired DNA repair in acute myeloid leukemia (AML) via ATG4B nuclear translocation. The findings illuminate a specific mechanism by which metabolic stress exacerbates genomic instability, suggesting new therapeutic strategies for AML.

• Cy5 Goat Anti-Mouse IgG (H+L) Antibody in Advanced Immunoass

  2026-08-05

  Unlock ultra-sensitive detection and robust signal amplification in immunoassays by leveraging the Cy5 Goat Anti-Mouse IgG (H+L) Antibody. This Cy5-conjugated secondary antibody empowers vaccine research and multiplexed workflows with enhanced specificity and reproducibility.

• AEBSF.HCl for Selective Lysosomal Protease Control in Necrop

  2026-08-04

  Explore the unique role of AEBSF.HCl (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride) in modulating lysosomal protease activity during necroptosis. This in-depth article unveils recent mechanistic insights and protocol guidance, distinguishing it from conventional inhibitor-focused content.

• Brassinolide: Catalyzing Translational Breakthroughs in Plan

  2026-08-04

  This thought-leadership article examines Brassinolide’s dual mechanistic roles in plant development and mammalian apoptosis, offering strategic guidance for translational researchers. By integrating new evidence from recent Arabidopsis studies and benchmarking against clinical-relevant cancer and diabetes models, it provides a roadmap for leveraging APExBIO’s Brassinolide (24-Epibrassinolide) across interdisciplinary domains, and highlights forward-looking opportunities and caveats for cross-kingdom applications.

• Targeting Fructose Metabolism via Aldose Reductase Inhibitio

  2026-08-03

  The reviewed paper highlights the pivotal role of dysregulated fructose metabolism, especially through the polyol pathway, in the malignancy and progression of aggressive cancers. By identifying aldose reductase as a key enzymatic target, the study presents a rationale for investigating aldose reductase inhibitors in cancer metabolism and therapeutic research.

7616 records 3/508 page Previous Next 12345 下5页 Last page